Ligand id: 4754
Name: empagliflozin
View more information in the IUPHAR Pharmacology Education Project: empagliflozin
|
Molecular properties generated using the CDK |
Classification ![]() |
|
Compound class | Natural product or derivative |
Approved drug? | Yes (FDA & EMA (2014)) |
IUPAC Name ![]() |
(2S,3R,4R,5S,6R)-2-[4-chloro-3-({4-[(3S)-oxolan-3-yloxy]phenyl}methyl)phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol |
International Nonproprietary Names ![]() |
|
INN number | INN |
9398 | empagliflozin |
Synonyms ![]() |
BI 10773 |
Database Links ![]() |
|
CAS Registry No. | 864070-44-0 (source: Scifinder) |
ChEBI | CHEBI:82720 |
ChEMBL Ligand | CHEMBL2107830 |
GtoPdb PubChem SID | 178101464 |
PubChem CID | 11949646 |
Search Google for chemical match using the InChIKey | OBWASQILIWPZMG-QZMOQZSNSA-N |
Search Google for chemicals with the same backbone | OBWASQILIWPZMG |
Search PubMed clinical trials | empagliflozin |
Search PubMed titles | empagliflozin |
Search PubMed titles/abstracts | empagliflozin |
Search UniChem for chemical match using the InChIKey | OBWASQILIWPZMG-QZMOQZSNSA-N |
Search UniChem for chemicals with the same backbone | OBWASQILIWPZMG |
Wikipedia | Empagliflozin |
Comments |
Empagliflozin is a member of the 'gliflozin' class of drugs which inhibit reabsorption of glucose in the kidney to lower blood sugar. It is the first glucose-lowering, antidiabetes therapy to be granted approval to reduce the risk of cardiovascular (CV) death in type 2 diabetes patients with CV disease. |